<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated on Wed, 29 Apr 2026 10:41:10 -0400 -->
<rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>    <title>Abeona Therapeutics Inc. (ABEO) - Presentations</title>
    <link>https://investors.abeonatherapeutics.com/presentations</link>
    <description>The latest news released by Abeona Therapeutics Inc.</description>
    <language>en-us</language>
    <generator>Equisolve</generator>
    <image>
      <url>https://d1io3yog0oux5.cloudfront.net/_193f3099ffb28d9ca669226c2dc7372a/abeonatherapeutics/logo.png</url>
      <title>Abeona Therapeutics Inc.</title>
      <link>https://www.abeonatherapeutics.com</link>
      <width>88</width>
      <height>31</height>
    </image>
    <item>
      <title>Topline Results from EB-101 Pivotal Phase 3 VIITAL™ Study</title>
      <link>https://investors.abeonatherapeutics.com/presentations/detal/4090/topline-results-from-eb-101-pivotal-phase-3-viital-study</link>
      <pubDate>Wed, 29 Apr 2026 10:41:10 -0400</pubDate>
      <guid isPermaLink="true">https://investors.abeonatherapeutics.com/presentations/detal/4090/topline-results-from-eb-101-pivotal-phase-3-viital-study</guid>
    </item>
    <item>
      <title>Corporate Presentation</title>
      <link>https://investors.abeonatherapeutics.com/presentations/detal/4239/corporate-presentation</link>
      <pubDate>Wed, 29 Apr 2026 10:41:10 -0400</pubDate>
      <guid isPermaLink="true">https://investors.abeonatherapeutics.com/presentations/detal/4239/corporate-presentation</guid>
    </item>
  </channel></rss>